Pacold, Michael E. http://orcid.org/0000-0003-3688-2378
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1K22CA212059)
V Foundation for Cancer Research (V2017-004)
Mary Kay Foundation (017-32)
Article History
First Online: 22 June 2020
Competing interests
: M.E.P. is a consultant to and holds equity in Raze Therapeutics and is the recipient of travel funds from Thermo Fisher Scientific.